Polo-like kinase 1 (PLK1) has been suggested to serve as an oncogene in most human cancers. The aim of our study is to present more evidence about the clinical and prognostic value of PLK1 in lung squamous cell carcinoma patients. The status of PLK1 was observed in lung adenocarcinoma, lung squamous cell carcinoma, and normal lung tissues through analyzing microarray dataset (GEO accession numbers: GSE1213 and GSE 3627). PLK1 mRNA and protein expressions were detected in lung squamous cell carcinoma and normal lung tissues by using quantitative real-time PCR (qRT-PCR) and immunohistochemistry. In our results, the levels of PLK1 in lung squamous cell carcinoma tissues were higher than that in lung adenocarcinoma tissues. Compared with paired adjacent normal lung tissues, the PLK1 expression was increased in lung squamous cell carcinoma tissues. Furthermore, high expression of PLK1 protein was correlated with differentiated degree, clinical stage, tumor size, lymph node metastasis, and distant metastasis. The univariate and multivariate analyses showed PLK1 protein high expression was an unfavorable prognostic biomarker for lung squamous cell carcinoma patients. In conclusion, high expression of PLK1 is associated with the aggressive progression and poor prognosis in lung squamous cell carcinoma patients.

Introduction
The incidence and mortality of lung cancer are the highest amongst malignant tumors worldwide [1]. Based on the 2015 Cancer Statistics in China, lung cancer alone is expected to account for 17% of all new cancer cases, and a total of estimated 4291600 new cancer cases occurred in 2015 [2]. In the United States, lung cancer also remains to be the leading cause of cancer deaths with a total of estimated 155870 lung cancer deaths in 2017 according to 2017 American Cancer Statistics [3]. Lung squamous cell carcinoma and lung adenocarcinoma are the main histological subtypes of lung cancer [4]. In recent years, the survival of lung adenocarcinoma patients have had a great progress due to the development of molecular target therapy (such as EGFR-TKI and ALK inhibition) [5,6]. However, lung squamous cell carcinoma still lacks effective molecular target for developing target therapy. Therefore, it is necessary to explore novel biomarkers for prognosis prediction and development of molecular target therapy for lung squamous cell carcinoma patients.

Polo-like kinase 1 (PLK1) is a member of the mitotic serine/threonine kinases family, which were originally identified in the fruitfly, Drosophila melanogaster from mutants with abnormal spindle poles [7].
PLK1 has been found to be overexpressed in many types of malignant human tumors and facilitate tumor cell proliferation [8]. In lung adenocarcinoma, down-regulation of PLK1 expression obviously suppressed cell proliferation and induced cell cycle arrest and apoptosis in vitro [9-11], and the combination of PLK1-shRNA and low-dose gemcitabine produced an additive antitumor activity on the lung tumors in vivo [12]. In non-small cell lung cancer, silenced PLK1 expression by iNOP-7-PLK1 siRNA reduced tumor growth in vitro and in vivo [13], and PLK1 was the target for miR-100 to regulate non-small cell lung cancer cell proliferation, apoptosis, and cell cycle [14]. The clinical study in non-small cell lung cancer patients showed that PLK1’s high expression was markedly associated with advanced clinical stage, higher tumor classification, and lymph node metastasis, and was an independent unfavorable prognostic biomarker for non-small cell lung cancer patients [15]. In our initial study, we analyzed microarray datasets, and found PLK1 overexpressed in lung squamous cell carcinoma tissues compared with lung adenocarcinoma tissues. We further confirmed the status of PLK1 mRNA and protein expressions in lung squamous cell carcinoma tissue samples. Thus, we supposed that PLK1 may serve as an important biomarker for lung squamous cell carcinoma patients. The aim of our study was to explore the clinical and prognostic significance of PLK1 in lung squamous cell carcinoma patients.

Materials and methods
Analysis of microarray data
Microarray dataset (GEO accession number: GSE1213) from five pairs of squamous lung cancer specimens and adjacent normal lung specimens was submitted by Wachi et al. [16]. Microarray dataset (GEO accession number: GSE 3627), which was composed of 42 lung adenocarcinoma specimens and 18 lung squamous cell carcinoma specimens, was submitted by Kuner et al. [17]. The differentially expressed genes were screened and identified by quantitative real-time PCR (qRT-PCR) for the following study.

Patients and specimens
The study was approved by the Ethical Committees of Affiliated Hospital of Hebei University. An informed consent was obtained from all the participants before enrollment in the study. The entire study was performed based on the Declaration of Helsinki. A total of 132 lung squamous cell carcinoma tissues and 33 adjacent normal lung tissues were collected at Affiliated Hospital of Hebei University between January 2008 and December 2015. Tissues were respectively stored in liquid nitrogen for qRT-PCR and formaldehyde solution for immunohistochemistry. None of the patients in the present study had received neoadjuvant antitumor treatment. Clinical staging and system treatment were based on the seventh edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual and National Comprehensive Cancer Network (NCCN) guidelines, respectively.

qRT-PCR
Total RNA was extracted from tissues’ cell lines using RNAiso Plus (Takara), and then reverse-transcribed to cDNAs using the PrimeScript RT Master Mix (Takara), according to manufacturer’s instructions. The LightCycler (Roche, U.S.A.) was selected to conduct the amplification of cDNAs using SYBR Premix Ex Taq™ II (Takara). The primers used for RT-PCR were purchased from Takara. Primers for the human PLK: forward primer, 5′-GATTCCACGGCTTTTTCGAG-3′; reverse primer, 5′-CCACACAGGGTCCTTCTCC-3′. Primers for the human GAPDH: forward primer, 5′-ACCACGTCCATGCCATCAC-3′; reverse primer, 5′-TCCACACCTTGTGCTGTA-3′. Relative expression was calculated via the comparative cycle threshold method and was normalized to the expression of GAPDH.

Immunohistochemistry
Immunohistochemical analysis was performed to measure PLK1 protein expression in 132 lung squamous cell carcinoma tissues and 33 adjacent normal lung tissues. In brief, slides were baked at 60°C for 1 h, followed by deparaffinization with xylene, and rehydrated. The sections were submerged in EDTA antigenic retrieval buffer and microwaved for antigen retrieval. They were then treated with 3% hydrogen peroxide in methanol to quench endogenous peroxidase activity, followed by incubation with 5% BSA to block nonspecific binding. Sections were incubated with anti-PLK1 (1:150 dilution, Abcam) overnight at 4°C. After washing, tissue sections were treated with secondary antibody, followed by incubation with conjugated horseradish peroxidase streptavidin. Tissue sections were then counterstained with Hematoxylin, dehydrated, and mounted. Finally, sections were viewed under a bright-field microscope.
Table 1 Expression of PLK1 protein between lung squamous cell carcinoma and normal bronchial epithelial tissues

| Group          | Cases | PLK1 High expression | PLK1 Low expression | P-value |
|----------------|-------|----------------------|---------------------|---------|
| Tumor tissues  | 132   | 72                   | 60                  | 0.001   |
| Normal tissues | 33    | 7                    | 26                  |         |

Evaluation of staining
The tissue sections stained immunohistochemically for PLK1 were reviewed and scored separately by two pathologists blinded to the clinical parameters. Any disagreements were arbitrated by the third pathologist. For PLK1 assessment, staining intensity was scored as 0: negative; 1: weak; 2: moderate; or 3: strong; and staining extent was scored as 0, 0%; 1, 1–10%; 2, 11–50%; 3, 51–80%; or 4, more than 80% positive cells. The final score was calculated by multiplication of these two variables. Low expression of PLK1 was defined as 0–6 score; high expression of PLK1 was defined as more than 6 score.

Statistical analysis
Diagrams were conducted using GraphPad Prism 5.0 and statistical analyses were accomplished using SPSS 17.0. The association between clinicopathological characteristics and PLK1 expression was determined using χ^2 tests. Survival analysis was performed using Kaplan–Meier method. Univariate and multivariate Cox regression models were used to evaluate prognostic significance. The comparison between the two groups was conducted using t test. P-values in all experiments were considered statistically significant at less than or equal to 0.05.

Ethics statement
The present study was approved by the Research Ethics Committee of Affiliated Hospital of Hebei University. The informed written consents were collected from all eligible patients and the entire study was performed based on the Declaration of Helsinki.

Results
PLK1 is overexpressed in lung squamous cell carcinoma
In order to explore novel biomarkers for lung squamous cell carcinoma patients, microarray datasets (GSE1213 and GSE 3627) were analyzed. Based on Kuner et al. [17] microarray data (GSE3267), PLK1 was found overexpressed in lung squamous cell carcinoma tissues compared with lung adenocarcinoma tissues (Figure 1A). Furthermore, we verified the status of PLK1 between lung squamous cell carcinoma and lung adenocarcinoma through qRT-PCR, and found that the levels of PLK1 mRNA was overexpressed in lung squamous cell carcinoma tissues compared with lung adenocarcinoma tissues with an average increase of 2.65-fold (P<0.001, Figure 1C).

Moreover, we observed that the expression of PLK1 was increased in lung squamous cell carcinoma tissues compared with paired adjacent normal lung tissues from Wachi et al. [16] microarray data (GSE1213) (Figure 1B). Compared with paired adjacent normal lung tissues, the levels of PLK1 mRNA was overexpressed in lung squamous cell carcinoma tissues with an average increase of 3.85-fold (P<0.001, Figure 1C). Furthermore, PLK1 protein expressions in 132 lung squamous cell carcinoma tissues and 33 adjacent normal lung tissues were detected by immunohistochemical staining (Figure 2A–H). We observed that PLK1 protein expression was increased in lung squamous cell carcinoma tissues in 54.5% (72/132) compared with adjacent normal tissues in 21.2% (7/33) (P=0.001, Table 1).

PLK1 protein expression is associated with malignant status of lung squamous cell carcinoma patients
The clinical significance of PLK1 protein expression in lung squamous cell carcinoma patients was explored in 132 lung squamous cell carcinoma tissue specimens through immunohistochemistry. The association between clinicopathological features and PLK1 protein expression in lung squamous cell carcinoma patients was summarized in Table 2. We observed that PLK1 protein's high expression positively correlated with differentiated degree (high or middle compared with low, P<0.001), clinical stage (I–II compared with III–IV, P<0.001), tumor size (T1–T2 compared with T3–T4, P<0.001), lymph node metastasis (N1 compared with N2–N3, P<0.001), and distant metastasis (M0 compared with M1, P=0.002). However, there were no significant relationships between PLK1 protein expression and age (P=0.592), gender (P=0.746), smoking (P=0.108), and tumor size (P=0.105).
Figure 1. The status of PLK1 in lung squamous cell carcinoma, lung adenocarcinoma, and normal lung tissues

(A) PLK1’s high expression was observed in lung squamous cell carcinoma tissues compared with lung adenocarcinoma tissues by microarray data (GSE3627). (B) Expression of PLK1 was increased in lung squamous cell carcinoma tissues compared with adjacent normal lung tissues through observation of microarray data (GSE1213). (C) PLK1 mRNA expression was detected in lung squamous cell carcinoma, lung adenocarcinoma, and normal lung tissues by qRT-PCR.

PLK1 protein overexpression is an unfavorable prognostic factor in lung squamous cell carcinoma patients

The prognostic value of PLK1 protein expression in lung squamous cell carcinoma patients was also explored in 132 lung squamous cell carcinoma tissue specimens through immunohistochemistry. Kaplan–Meier survival analysis showed lung squamous cell carcinoma patients, that expressed high level of PLK1 protein, had lower overall survival compared with patients with low level of PLK1 protein expression (P<0.001, Figure 2). Moreover, we conducted univariate analysis and identified five prognostic parameters: clinical stage, tumor size, lymph node metastasis, distant metastasis, and PLK1 protein expression. Finally, multivariate analysis showed PLK1 protein’s high expression was an independent poor prognostic factor for lung squamous cell carcinoma patients (hazard ratio (HR) =1.926, 95% CI: 1.199–3.093, P=0.007, Table 3).

Discussion

PLK1 is a member of the family of mitotic serine/threonine kinases, which are characterized by a C-terminal polo-box domain and a conserved N-terminal catalytic domain [18,19]. PLK1 homologs were originally identified as Polo in Drosophila, Pol1 in Schizosaccharomyces pombe, Cdc5 in Saccharomyces cerevisiae, and Plx1 in Xenopus [20,21]. PLK1 plays a key role in mitotic entry of proliferating cells and regulates many aspects of mitosis [22]. PLK1 protein levels are lowest during G1, elevate S, and enrich their greatest concentration in G2/M [23].

Recently, PLK1 has been found to be overexpressed in many types of human cancers such as hepatocellular carcinoma [24-28], glioma [29-32], colorectal cancer [33-38], gastric cancer [39-42], pancreatic cancer [43-45],
Figure 2. Immunohistochemical staining and pronostic value of PLK1 in lung squamous cell carcinoma

(A–H) Immunohistochemical staining of PLK1 in lung squamous cell carcinoma tissues and adjacent normal tissues. (A) Negative expression of PLK1 in lung squamous cell carcinoma tissue. (B) Weak expression of PLK1 in lung squamous cell carcinoma tissue. (C) Moderate expression of PLK1 in lung squamous cell carcinoma tissue. (D) Strong expression of PLK1 in lung squamous cell carcinoma tissue. (E) Negative expression of PLK1 in normal bronchial epithelial tissues. (F) Weak expression of PLK1 in normal bronchial epithelial tissues. (G) Moderate expression of PLK1 in normal bronchial epithelial tissues. (H) Strong expression of PLK1 in normal bronchial epithelial tissues. (I) PLK1 protein overexpression is an unfavorable prognostic factor in lung squamous cell carcinoma patients. Kaplan–Meier survival analysis of overall survival duration in 132 lung squamous cell carcinoma patients according to PLK1 protein expression.

lymphomas [46,47], ovarian cancer [48,49], bladder cancer [50], prostate cancer [51], breast cancer [52,53], and esophageal cancer [54]. In non-small- cell lung cancer, PLK1 has been shown to be overexpressed in tumor tissues and cell lines [15,55]. Similarly, our study also showed that PLK1 expression was increased in lung cancer tissues. Interestingly, we further found the levels of PLK1 in lung squamous cell carcinoma tissues were higher than that in lung adenocarcinoma tissues. The difference of PLK1 between lung squamous cell cancer and lung adenocarcinoma would be most likely to be due to tumor heterogeneity. Thus, we sequentially explored that clinical significance of PLK1 in lung squamous cell carcinoma patients, and found high expression of PLK1 protein was correlated with
Table 2 Associations between clinicopathologic factors and PLK1 in lung squamous cell carcinoma patients

| Characteristics          | n   | PLK1                |                |                   |
|--------------------------|-----|---------------------|----------------|-------------------|
|                          |     | High expression     | Low expression | P-value           |
| Gender                   |     |                     |                |                   |
| Female                   | 45  | 26                  | 19             | 0.592             |
| Male                     | 87  | 46                  | 41             |                   |
| Age (y)                  |     |                     |                |                   |
| <50                      | 53  | 28                  | 25             | 0.746             |
| ≥50                      | 79  | 44                  | 35             |                   |
| Smoking                  |     |                     |                |                   |
| No                       | 76  | 46                  | 30             | 0.108             |
| Yes                      | 56  | 26                  | 30             |                   |
| Differentiated degree    |     |                     |                |                   |
| High or middle           | 79  | 32                  | 47             | <0.001            |
| Low                      | 53  | 40                  | 13             |                   |
| Clinical stage           |     |                     |                |                   |
| I–II                     | 54  | 14                  | 40             | <0.001            |
| III–IV                   | 78  | 58                  | 20             |                   |
| Tumor size               |     |                     |                |                   |
| T1–T2                    | 69  | 33                  | 36             | 0.105             |
| T3–T4                    | 63  | 39                  | 24             |                   |
| Lymph node metastasis    |     |                     |                |                   |
| N0–N1                    | 62  | 20                  | 42             | <0.001            |
| N2–N3                    | 70  | 52                  | 18             |                   |
| Distant metastasis       |     |                     |                |                   |
| M0                       | 121 | 61                  | 60             | 0.002             |
| M1                       | 11  | 11                  | 0              |                   |

Table 3 Univariate and multivariate analyses of overall survival in lung squamous cell carcinoma patients

| Parameters                          | Univariate analysis | Multivariate analysis |
|-------------------------------------|---------------------|-----------------------|
|                                     | P-value  | HR     | 95% CI  | P-value | HR     | 95% CI  |
| Gender (Female compared with male)  | 0.471    | 1.185  | 0.747–1.882 |         |         |         |
| Age (<50 compared with ≥50 years)   | 0.149    | 0.737  | 0.487–1.116 |         |         |         |
| Smoking (No compared with yes)      | 0.653    | 1.102  | 0.723–1.680 |         |         |         |
| Differentiated degree (High or middle compared with low) | 0.869 | 0.965 | 0.629–1.479 |         |         |         |
| Clinical stage (I–II compared with III–IV) | <0.001 | 3.214 | 2.009–5.141 | 0.448 | 0.615 | 0.175–2.160 |
| Tumor size (T1–T2 compared with T3–T4) | 0.006 | 1.809 | 1.189–2.752 | 0.076 | 1.517 | 0.958–2.404 |
| Lymph node metastasis (N0–N1 compared with N2–N3) | <0.001 | 3.614 | 2.285–5.716 | 0.024 | 3.997 | 1.197–13.347 |
| Distant metastasis (M0 compared with M1) | <0.001 | 6.037 | 3.030–12.030 | 0.013 | 2.541 | 1.218–5.302 |
| PLK1 expression (Low compared with high) | <0.001 | 2.591 | 1.682–3.991 | 0.007 | 1.926 | 1.199–3.093 |

differentiated degree, clinical stage, tumor size, lymph node metastasis, and distant metastasis. Analogous to a report from Wang et al. [15], their research showed that PLK1 overexpression was markedly associated with advanced clinical stage, higher tumor classification, and lymph node metastasis in non-small cell lung cancer patients [15]. In colorectal cancers, Takahashi et al. [33] demonstrated that elevated expression of PLK1 was associated with pT (primary tumor invasion), pN (regional lymph nodes), and the Dukes’ classification. Moreover, Weichert et al. [56]
reported that PLK1 expression was correlated with tumor grade, vascular invasion, HER2 expression, and markers of proliferative activity in breast cancer patients. In hepatocellular carcinoma patients, He et al. [26] suggested that the PLK1 positive expression was correlated with venous invasion tumor nodules and Edmondson grade. Liu et al. [57] found that PLK1 expression had associations with systemic symptoms (fever, night sweats, and weight loss), lactate dehydrogenase (LDH) level, and International Prognostic Index (IPI) scores. These studies consistently suggested that PLK1 expression was positively associated with malignant status of human cancers.

In recent decades, PLK1 overexpression has been suggested to serve as a prognostic factor in most types of human cancers. Linton et al. [58] showed that PLK1 expression in over 10% of tumor cells is associated markedly with an unfavorable prognosis in malignant pleural mesothelioma patients. Moreover, Yamada et al. [24] reported hepatoblastoma patients with high expression of PLK1 represented obviously poorer outcomes than those with PLK1 low expression. In children with medulloblastoma, PLK1 was independently correlated with poor outcomes through using Cox regression analyses in two patient cohorts [59]. In ovarian cancer patients, Weichert et al. [48] found that PLK1 overexpression was an independent unfavorable prognostic marker through univariate and multivariate survival analyses. Doniz et al. [60] suggested high expression of PLK1 was correlated with shorter cancer-specific overall survival and disease-free survival in breast cancer patients. In non-small cell lung cancer patients, Wang et al. [15] revealed that high PLK1 protein expression was an independent prognostic biomarker. In the present study, we further presented the evidence that lung squamous cell carcinoma patients that expressed high level of PLK1 protein had lower overall survival compared with patients with low level of PLK1 protein expression, and PLK1 protein high expression was an independent poor prognostic factor based on univariate and multivariate survival analyses.

Recently, PLK1 inhibitors have been considered to be anticancer drug candidates [8]. PLK1 inhibitors include BI 2536 (Boehringer Ingelheim Pharma, Germany) [61-63], Volasertib (BI 6727; Boehringer Ingelheim Pharma, Germany) [64], GS4661364A (GlaxoSmithKline, U.K.) [65], HMN-214 (Nippon Shinyaku Co. Ltd, Japan) [66], NMS-P937 (Nerviano Medical Science, Italy) [67], TAK-960 (Tekmira Pharmaceuticals Co., Canada) [68], and Rigosertib (Onconova Therapeutics Inc., U.S.A.) [69]. Nowadays, PLK1 inhibitors are being used in several types of cancer patients to monitor their efficacy and safety in clinical trials. BI 2536 was the first selective PLK1 inhibitor investigated in clinical trials with patients who have various advanced and/or metastatic solid tumors including non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, and ovarian cancer [61]. This first-in-man, phase I, dose-escalation study showed that BI 2536 was favorable in terms of manageable toxicity, high distribution into tissue, and favorable efficacy in cancer patients, which initiated further clinical studies [61]. The phase II trial with BI 2536 was carried out in 95 stage IIIB/IV non-small cell lung cancer to have modest clinical efficacy [62]. This report suggested modest efficacy and acceptable safety of BI 2536 monotherapy in relapse non-small cell lung cancer patients. Unfortunately, BI 2536 had a relatively poor clinical efficacy, with 4.2% patients achieving a partial response [62]. Thus, further clinical studies were mainly carried out in combination with other anticancer drugs rather than monotherapy of BI 2536. The combination therapy with the standard-dose pemetrexed was performed in 41 patients with non-small cell lung cancer [63]. This open-label, phase I study showed that BI 2536 (200 mg) combined with standard-dose pemetrexed has an acceptable safety profile, and had a relatively favorable clinical efficacy, with 95.1% patients evaluating tumor response [63]. In our study, we found that the levels of PLK1 were higher in in lung squamous cell carcinoma tissues compared with lung adenocarcinoma tissues, and PLK1 high expression was the aggressive progression and poor prognosis in lung squamous cell carcinoma patients, which implied that PLK inhibitors may have surprising clinical efficacy in lung squamous cell carcinoma patients. Further studies would be needed to verify this supposition and evaluate the clinical efficacy of PLK inhibitors in lung squamous cell carcinoma patients.

In conclusion, PLK1 expression is increased in lung squamous cell carcinoma tissues, and associated with malignant status and prognosis in lung squamous cell carcinoma patients. PLK1 is an independent unfavorable prognostic factor for lung squamous cell carcinoma patients.

Competing interests
The authors declare that there are no competing interests associated with the manuscript.

Funding
The authors declare that there are no sources of funding to be acknowledged.

Author contribution
Hefei Li and Haibo Wang designed the study; Hefei Li and Haibo Wang analyzed the data and wrote the manuscript; Hefei Li, Haibo Wang, Zhengqing Sun, Qiang Guo, Hongyun Shi and Youchao Jia collected all date and performed all the experiments.
Abbreviations
HR, hazard ratio; PLK1, polo-like kinase 1; 95% CI, 95% confidence interval.

References
1 Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J. and Jemal, A. (2015) Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108
2 Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F. et al. (2016) Cancer statistics in china, 2015. CA Cancer J. Clin. 66, 115–132
3 Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer statistics, 2017. CA Cancer J. Clin. 67, 7–30
4 Herbst, R.S., Heymach, J.V. and Lippman, S.M. (2008) Lung cancer. N. Engl. J. Med. 359, 1367–1380
5 Mayo, C., Bertran-Ànlillo, J., Molina-Vila, M.A., Gimenez-Capitan, A., Costa, C. and Rosell, R. (2012) Pharmacogenetics of egfr in lung cancer: perspectives and clinical applications. Pharmacogenomics 13, 789–802
6 Crotea, P. and Kolesar, J.M. (2015) Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer. Am. J. Health Syst. Pharm. 72, 1456–1462
7 Degenhardt, Y. and Lampkin, T. (2010) Targeting polo-like kinase in cancer therapy. Clin. Cancer Res. 16, 384–389
8 Yim, H. (2013) Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs 24, 999–1006
9 Zhou, Q., Su, Y. and Bai, M. (2008) Effect of antisense rna targeting polo-like kinase 1 on cell growth in a549 lung cancer cells. J. Huazhong Univ. Sci. Technolog. Med. Sci. 28, 22–26
10 Zhou, Q., Bai, M. and Su, Y. (2005) Effect of antisense rna targeting Polo-like kinase 1 on cell cycle of lung cancer cell line A549. Ai Zheng 24, 149–154
11 Zhou, Q., Bai, M. and Su, Y. (2004) Effect of antisense RNA targeting Polo-like kinase 1 on cell cycle and proliferation in A549 cells. Chin. Med. J. (Engl.) 117, 1642–1649
12 Zhao, X.Y., Nie, C.L., Liang, S.F., Yuan, Z., Deng, H.X. and Wei, Y.Q. (2012) Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based rna interference against plk1. Biomed. Pharmacother. 66, 597–602
13 McCarroll, J.A., Dwarte, T., Baigude, H., Dang, J., Yang, L., Erlich, R.B. et al. (2015) Therapeutic targeting of polo-like kinase 1 using rna-interfering nanoparticles (inops) for the treatment of non-small cell lung cancer. Oncotarget 6, 12020–12034
14 Liu, J., Lu, K.H., Liu, Z.L., Sun, M., De, W. and Wang, Z.X. (2012) MicromrNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. BMC Cancer 12, 519
15 Wang, Z.X., Xue, D., Liu, Z.L., Lu, B.B., Bian, H.B., Pan, X. et al. (2012) Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer. Int. J. Biochem. Cell Biol. 44, 200–210
16 Wachi, S., Yoneda, K. and Wu, R. (2005) Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 21, 4205–4208
17 Kuner, R., Muley, T., Meister, M., Ruschhaupt, M., Buness, A., Xu, E.C. et al. (2009) Pharmacogenetics of egfr in lung cancer: perspectives and clinical applications. Pharmacogenomics 10, 1456–1462
18 Reagan-Shaw, S. and Ahmad, N. (2005) Polo-like kinase (plk) 1 as a target for prostate cancer management. IUBMB Life 57, 677–682
19 Lowery, D.M., Lim, D. and Yaffe, M.B. (2005) Structure and function of polo-like kinases. Prog. Cell Cycle Res. 5, 327–334
20 Palmsino, N.D. and Kesner, M.T. (2015) Polo-like kinase and its inhibitors: Ready for the match to start? Ann. J. Hematol. 90, 1071–1076
21 Golestyan, R.M., Mundt, K.E., Fry, A.M. and Nigg, E.A. (1995) Cell cycle regulation of the activity and subcellular localization of plk1, a human protein kinase implicated in mitotic spindle function. J. Cell Biol. 129, 1617–1628
22 McCarroll, J.A., Dwarte, T., Baigude, H., Dang, J., Yang, L., Erlich, R.B. et al. (2015) Therapeutic targeting of polo-like kinase 1 using rna-interfering nanoparticles (inops) for the treatment of non-small cell lung cancer. Oncotarget 6, 12020–12034
23 Ackermann, S., G, 28 Sun, W., Su, Q., Cao, X., Shang, B., Chen, A., Yin, H. et al. (2014) High expression of polo-like kinase 1 is associated with early development of hepatoblastomas and the corresponding normal livers: Identification of high expression of the plk1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 33, 5901–5911
24 Chen, X.J., Wu, L.M., Xu, X.B., Feng, X.W., Xie, H.Y., Zhang, M. et al. (2007) Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi 45, 1354–1358
25 He, Z.L., Zheng, H., Lin, H., Miao, X.Y. and Zhong, D.W. (2009) Overexpression of Polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J. Gastroenterol. 15, 4177–4182
26 Palmsino, N.D. and Kesner, M.T. (2015) Polo-like kinase and its inhibitors: Ready for the match to start? Ann. J. Hematol. 90, 1071–1076
27 Pellegrino, R., Calvisi, D.F., Ladu, S., Ehemann, V., Stanisic, T., Evert, M. et al. (2010) Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 51, 857–868
28 Sun, W., Su, Q., Cao, X., Shang, B., Chen, A., Yin, H. et al. (2014) High expression of polo-like kinase 1 is associated with early development of hepatocellular carcinoma. Int. J. Genomics 2014, 312130
29 Ackermann, S., Goesser, F., Schulte, J.H., Schramm, A., Ehemann, V., Hero, B. et al. (2011) Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma. Clin. Cancer Res. 17, 731–741
30 Harris, P.S., Venkataraman, S., Alimova, I., Birks, D.K., Donson, A.M., Knipstein, J. et al. (2012) Polo-like kinase 1 (plk1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. BMC Cancer 12, 80
31 Cheng, M.W., Wang, B.C., Weng, Z.Q. and Zhu, X.W. (2012) Clinicopathological significance of polo-like kinase 1 (plk1) expression in human malignant glioma. Acta Histochem. 114, 503–509
32 Amani, V., Prince, E.W., Alimova, I., Balakrishnan, I., Birks, D., Donson, A.M. et al. (2016) Polo-like kinase 1 as a potential therapeutic target in diffuse intrinsic pontine glioma. *BMC Cancer* **16**, 647

33 Takahashi, T., Sano, B., Nagata, T., Kato, H., Sugiyama, Y., Kunieda, K. et al. (2003) Polo-like kinase 1 (plk1) is overexpressed in primary colorectal cancers. *Cancer Sci.* **94**, 148–152

34 Weiichert, W., Kristiansen, G., Schmidt, M., Gekeler, V., Noske, A., Niesporek, S. et al. (2005) Polo-like kinase 1 expression is a prognostic factor in human colon cancer. *World J. Gastroenterol.* **11**, 5644–5650

35 Rodel, F., Keppner, S., Capalbo, G., Bashary, R., Kaufmann, M., Rodel, C. et al. (2010) Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. *Am. J. Pathol.* **177**, 918–929

36 Han, D.P., Zhu, Q.L., Cui, J.T., Wang, P.X., Qu, S., Cao, Q.F. et al. (2012) Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. *Med. Sci. Monit.* **18**, BR237–BR246

37 Tut, T.G., Lim, S.H., Dissanayake, I.U., Descallar, J., Chua, W., Ng, W. et al. (2015) Upregulated polo-like kinase 1 expression correlates with inferior survival outcomes in rectal cancer. *PloS ONE* **10**, e0129313

38 Fernandez-Acenero, M.J., Cortes, D., Gomez del Pulgar, T., Cebrian, A., Estrada, L., Martinez-Userso, J. et al. (2016) Plk-1 expression is associated with histopathological response to neoadjuvant therapy of hepatic metastasis of colorectal carcinoma. *Pathol. Oncol. Res.* **22**, 377–383

39 Jang, Y.J., Kim, Y.S. and Kim, W.H. (2006) Oncogenic effect of polo-like kinase 1 expression in human gastric carcinomas. *Int. J. Oncol.* **29**, 589–594

40 Weiichert, W., Ulrich, A., Schmidt, M., Gekeler, V., Noske, A., Niesporek, S. et al. (2006) Expression patterns of polo-like kinase 1 in human gastric cancer. *Cancer Sci.* **97**, 271–276

41 Lan, B., Liu, B.Y., Chen, X.H., Qu, Y., Zhang, X.Q., Cai, Q. et al. (2007) Polo like kinase 1 expression and prognostic value in gastric carcinomas. *Zhonghua Wei Chang Wei Ke Za Zhi* **10**, 70–72

42 Yao, H., Yang, Z. and Li, Y. (2010) Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach. *Zhong Nan Da Xue Yue Bao Yi Xue Ban* **35**, 1080–1084

43 Gray, Jr, P.J., Bearss, D.J., Han, H., Nagle, R., Tsao, M.S., Dean, N. et al. (2004) Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. *Mol. Cancer Ther.* **3**, 641–646

44 Weiichert, W., Schmidt, M., Jacob, J., Gekeler, V., Langrehr, J., Neuhaus, P. et al. (2005) Overexpression of polo-like kinase 1 is a common and early event in pancreatic cancer. *Cancer Research* **55**, 259–265

45 Song, B., Liu, X.S., Rice, S.J., Kuang, S., Elzey, B.D., Konieczny, S.F. et al. (2013) Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. *Mol. Cancer Ther.* **12**, 58–68

46 Stutz, N., Niital, M. and Wood, G.S. (2011) Polo-like kinase 1 (plk1) in cutaneous t-cell lymphoma. *Br. J. Dermatol.* **164**, 814–821

47 Niital, M., Stutz, N., Schmitt, T., Ahmad, N. and Wood, G.S. (2011) Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis. *Cell Cycle* **10**, 1303–1311

48 Weiichert, W., Denkert, C., Schmidt, M., Gekeler, V., Wolf, G., Kobel, M. et al. (2004) Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. *Br. J. Cancer* **90**, 815–821

49 Zhang, R., Shi, H., Ren, F., Liu, H., Zhang, M., Deng, Y. et al. (2015) Misregulation of polo-like protein kinase 1, p53 and p21waf1 in epithelial ovarian cancer suggests poor prognosis. *Oncol. Rep.* **33**, 1235–1242

50 Zhang, Z., Zhang, G. and Kong, C. (2013) High expression of polo-like kinase 1 is associated with the metastasis and recurrence in uterine carcinoma of bladder. *Urol. Oncol.* **31**, 1222–1230

51 Weiichert, W., Schmidt, M., Gekeler, V., Denkert, C., Stephan, C., Jung, K. et al. (2004) Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. *Prostate* **60**, 240–245

52 King, S.I., Purdie, C.A., Bray, S.E., Quintin, P.R., Jordan, L.B., Thompson, A.M. et al. (2012) Immunohistochemical detection of polo-like kinase-1 (plk1) in primary breast cancer is associated with tp53 mutation and poor clinical outcome. *Breast Cancer Res.* **14**, R40

53 Maire, V., Nemati, F., Richardson, M., Vincent-Salomon, A., Tesson, B., Rigali, G. et al. (2013) Polo-like kinase 1: A potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. *Cancer Res.* **73**, 813–823

54 Dibb, M., Han, N., Choudhury, J., Hayes, S., Valentine, H., West, C. et al. (2012) The foxm1-plk1 axis is commonly upregulated in oesophageal adenocarcinoma. *Br. J. Cancer* **107**, 1766–1775

55 Xu, C., Li, S., Chen, T., Hu, H., Ding, C., Xu, Z. et al. (2016) Mir-296-5p suppresses cell viability by directly targeting plk1 in non-small cell lung cancer. *Oncol. Rep.* **35**, 497–503

56 Weiichert, W., Kristiansen, G., Winzer, K.J., Schmidt, M., Gekeler, V., Noske, A. et al. (2005) Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. *Virochows Arch.* **446**, 442–450

57 Liu, L., Zhang, M. and Zou, P. (2008) Polo-like kinase 1 as a new target for non-Hodgkin's lymphoma treatment. *Oncology* **74**, 96–103

58 Linton, A., Cheng, Y.Y., Griggs, K., Kirschner, M.B., Gattani, S., Srikaran, S. et al. (2014) An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. *Br. J. Cancer* **110**, 510–519

59 Triscott, J., Lee, C., Foster, C., Manoranjan, B., Pambid, M.R., Berns, R. et al. (2013) Personalizing the treatment of pediatric medulloblastoma: polo-like kinase 1 as a molecular target in high-risk children. *Cancer Res.* **73**, 6734–6744

60 Donizy, P., Halon, A., Surovik, P., Kaczorowski, M., Kozyra, C. and Matkowski, R. (2016) Augmented expression of polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up. *Oncol. Lett.* **12**, 1667–1674

61 Mross, K., Frost, A., Steinbild, S., Hedbom, S., Rentschler, J., Kaiser, R. et al. (2008) Phase I dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors. *J. Clin. Oncol.* **26**, 5511–5517

62 Sebastian, M., Reck, M., Waller, C.F., Kortsik, C., Frickhofen, N., Schuler, M. et al. (2010) The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. *J. Thorac. Oncol.* **5**, 1060–1067
63 Ellis, P.M., Chu, Q.S., Leighl, N., Laurie, S.A., Fritsch, H., Gaschler-Markfeldt, B. et al. (2013) A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Clin. Lung Cancer 14, 19–27

64 Rudolph, D., Steegmaier, M., Hoffmann, M., Grauert, M., Baum, A., Quant, J. et al. (2009) BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin. Cancer Res. 15, 3094–3102

65 Olmos, D., Barker, D., Sharma, R., Brunetto, A.T., Yap, T.A., Taegtmeyer, A.B. et al. (2011) Phase I study of gsk461364, a specific and competitive polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res. 17, 3420–3430

66 Garland, L.L., Taylor, C., Pilkington, D.L., Cohen, J.L. and Von Hoff, D.D. (2006) A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin. Cancer Res. 12, 5182–5189

67 Valsasina, B., Beria, I., Alli, C., Atzani, R., Avanzi, N., Ballinari, D. et al. (2012) NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol. Cancer Ther. 11, 1006–1016

68 Nie, Z., Feher, V., Natala, S., McBride, C., Kiryanov, A., Jones, B. et al. (2013) Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1). Bioorg. Med. Chem. Lett. 23, 3662–3666

69 Nuthalapati, S., Zhou, Q., Guo, P., Lv, H., Cosenza, S., Reddy, M.V. et al. (2012) Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, EstybonTM) and ON013105, for brain tumor chemotherapy. Pharm. Res. 29, 2499–2511